psychoneuro, Table of Contents psychoneuro 2007; 33(5): 202-203DOI: 10.1055/s-2007-984849 Blickpunkt © Georg Thieme Verlag KG Stuttgart · New York Optimierung der Schizophrenietherapie - Compliance durch effektives Gewichtsmanagement unterstützen Recommend Article Abstract Full Text References Literatur 01 Beasley jr CM . et al . A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse. J Clin Psychopharmacology. 2003; 23 (6) 582-594 02 Czekalla J . et al . Improvement of Suicidal Ideation and Medication Acceptance under Treatment with Olanzapine Disintegrating and Coated Olanzapine Tablets. Results from a Prospective Multi-Center Study of Acutely Ill Psychiatric Inpatients. Schizophr Res. 2004; 67 (Suppl 1) 214 03 Hennen J . et al . Weight Gain During Treatment of Bipolar I Patients with Olanzapine. J Clin Psychiatry. 2004; 65 1679-1687 04 Hoffmann VP . et al . Wellness Intervention for Patients with Serious and Persistent Mental Illness. J Clin Psychiatry. 2005; 66 (12) 1576-1579 05 Hundemer HP . et al . BELA - Ein neues Psychoedukationsprogramm zum Ernährungsmanagement bei psychiatrischen Patienten. Posterpräsentation beim Jahreskongress der Deutschen Gesellschaft für Innere Medizin (DGIM) 2006, 22.-26. April, Wiesbaden. 06 Kinon BJ . et al . Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders. J Clin Psychopharmacol. 2005; 25 (3) 255-258 07 Kinon BJ . et al . Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia. J Clin Psychiatry. 2001; 62 (2) 92-100 08 Littrell KH . et al . The Effects of an Educational Intervention on Antipsychotic-Induced Weight Gain. Journal of Nursing Scholarship. 2003; 35 (3) 237-241 09 Liu-Seifert H . et al . Discontinuation from Schizophrenia Treatment is Driven by Poor Symptom Response. A Post-Hoc Analysis of 4 Atypical Antipsychotics Combined. BMC Medicine 2005; 3 (21). 10 National Institute for Health and Clinical Excellence: NICE Clinical Guideline 38. Bipolar Disorder. The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. Juli 2006. Online publiziert unter www.nice.org.uk/CG038 . 11 Novick D . et al . Effectiveness of Antipsychotic Treatment in Outpatients with Schizophrenia. 36-Month Results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study. Posterpräsentation beim Kongress der American Psychiatric Association 2006, 20.-25. Mai, Toronto, Kanada. 12 Novick D . et al . Factors Associated with Remission in Schizophrenia: 36-Month Results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study. Posterpräsentation beim Kongress der American Psychiatric Association 2006, 20.-25. Mai, Toronto, Kanada. 13 Pendlebury J . et al . Long Term Maintenance of Weight Loss in Patients With Severe Mental Illness Through a Behavioural Programme in the UK. Posterpräsentation beim European College of Neuropsychopharmacology 2005, 22.-26. Oktober, Amsterdam. 14 Yatham LN . et al . Canadian Network for Mood and Anxiety Treatments (CANMAT) Guidelines for the Management of Patients with Bipolar Disorder: Consensus and Controversies. Bipolar Disord. 2005; 7 (Suppl 3) 5-69 15 Zyprexa® Fachinformation.
